Compare CLOV & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLOV | FTRE |
|---|---|---|
| Founded | 2014 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | N/A | N/A |
| Metric | CLOV | FTRE |
|---|---|---|
| Price | $2.58 | $17.93 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 8 |
| Target Price | $4.23 | ★ $12.64 |
| AVG Volume (30 Days) | ★ 4.3M | 1.6M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,773,564,000.00 | ★ $2,759,900,000.00 |
| Revenue This Year | $41.68 | $3.17 |
| Revenue Next Year | $37.69 | $0.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 32.15 | 1.88 |
| 52 Week Low | $2.12 | $3.97 |
| 52 Week High | $4.87 | $20.26 |
| Indicator | CLOV | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 47.32 | 80.60 |
| Support Level | $2.41 | $15.55 |
| Resistance Level | $2.74 | $16.42 |
| Average True Range (ATR) | 0.10 | 1.13 |
| MACD | 0.02 | 0.23 |
| Stochastic Oscillator | 36.76 | 96.29 |
Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.